One of the key growth parameters is 15.5 per cent growth in number of patient visits with increase in revenue per patient (5.4 per cent) and revenue per test (8.5 per cent)
Metropolis witnessed robust operating and financial performance with good revenue growth maintaining overall margin and faster than industry benchmarks. One of the key growth parameters is a 15.5 per cent growth in number of patient visits with increase in revenue per patient (5.4 per cent) and revenue per test (8.5 per cent).
FY’19 continued to be a year of aggressive network expansion for the company. Its laboratory network grew to 119 from 106 in FY2018, majority through asset-light ‘Lab on Lease’ model.
Its patient service network of owned patient service centres (PSCs), assisted referral centres (ARCs) and third party PSCs grew 5.5x times between FY16-19 of which 79 per cent were added in the last two years (40 per cent growth in FY19). As this young network matures, it is expected to contribute to rapid short and midterm future growth.
Commenting on the annual results, Ameera Shah, Managing Director, Metropolis Healthcare said “I am happy to share the first financial performance of our company as a listed entity. FY19 has ended on a positive note for us as the company delivered a healthy topline. We expect short and midterm future growth owing to fast paced network expansion and execution. We will further strengthen our efforts towards differentiating our superior customer experience, delivering quality results and improving our technological capabilities.
We will continue to increase our retail contribution in focus cities and impact the lives of Indians while assisting them with quality results for routine and specialised tests. We will walk the extra mile for our patients who trust us during their most anxious moments during illnesses.”